About us

We have extensive experience in collaborating in multi-country studies

New era of collaboration

On the 11th of November 2020 a contract-based alliance of ENCePP research centres called the SIGMA Consortium was launched. The launch of the SIGMA Consortium heralded a new era of collaboration to better understand safety and effectiveness of medical interventions. Research institutions compete for resources to carry out research; SIGMA aims to address this challenge by integrating expertise and data from multiple European Research Centres.

This collaborative research initiative, designed to be the ‘go-to’ organization for state-of-the-art methodological pharmacoepidemiology/RWE research, was assembled to enable multi-country studies using common analyses to study responses to treatments in large populations.

Proposal request form

Mission and Vision

The SIGMA Consortium’s VISION is to provide best evidence on the use, benefits and harms of medications, vaccines and devices for the betterment of public health and patient care.

Its MISSION is to provide trusted pharmacoepidemiologic and real-world evidence (PE/RWE) research through a European federated professional network of excellence based on the ENCePP Code of Conduct. The SIGMA consortium welcomes collaborations with other groups and networks.

Members of SIGMA

Our objective

SIGMA Executive Committee start up members Prof Ron Herings (Netherlands) and Dr Susana Perez-Gutthann (Spain) said “The benefits and risks of treatments are of concern to every citizen. Our objective is to clarify and quantify these treatment effects for the citizens of Europe.”

info@sigmaconsortium.eu